133 related articles for article (PubMed ID: 6378798)
21. Suppression of Sendai virus growth by treatment with N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl-L-lysine in mice.
Ishihara C; Mizukoshi N; Iida J; Kato K; Yamamoto K; Azuma I
Vaccine; 1987 Dec; 5(4):295-301. PubMed ID: 2448969
[TBL] [Abstract][Full Text] [Related]
22. Inflammatory cytokine production induced by an analogue of muramyl dipeptide MDP-Lys(L18) in rat macrophage cultures and dog synovial fluid.
Sugawara T; Takada S; Miyamoto M; Nomura M; Kato M
Inflammation; 1996 Feb; 20(1):43-56. PubMed ID: 8926048
[TBL] [Abstract][Full Text] [Related]
23. Stimulation of mouse resistance to bacterial infection with muramyl dipeptide glycoside.
Kalyuzhin OV; Kalina NG; Bashtanenko AF; Shkalev MV; Kuzovlev FN; Kalyuzhin VV
Bull Exp Biol Med; 2003 May; 135(5):452-5. PubMed ID: 12910284
[TBL] [Abstract][Full Text] [Related]
24. Enhancing effect of Salmonella enteritidis SPA on nonspecific resistance.
Uchiya K; Sugihara H
Kansenshogaku Zasshi; 1989 May; 63(5):463-70. PubMed ID: 2550565
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of host resistance against Trypanosoma cruzi infection by the immunoregulatory agent muramyl dipeptide.
Kireszenbaum F; Ferraresi RW
Infect Immun; 1979 Jul; 25(1):273-8. PubMed ID: 113344
[TBL] [Abstract][Full Text] [Related]
26. Stimulation of nonspecific host resistance to infection induced by muramyldipeptides.
Matsumoto K; Ogawa H; Nagase O; Kusama T; Azuma I
Microbiol Immunol; 1981; 25(10):1047-58. PubMed ID: 7031443
[TBL] [Abstract][Full Text] [Related]
27. Curative properties of muramyl dipeptide in experimental Naegleria meningoencephalitis.
Ferrante A; Lederer E
Trans R Soc Trop Med Hyg; 1986; 80(2):323-6. PubMed ID: 3538525
[TBL] [Abstract][Full Text] [Related]
28. Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogues.
Saiki I; Saito S; Fujita C; Ishida H; Iida J; Murata J; Hasegawa A; Azuma I
Vaccine; 1988 Jun; 6(3):238-44. PubMed ID: 2844032
[TBL] [Abstract][Full Text] [Related]
29. Intrapleural therapy with MDP-Lys (L18), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer.
Yanagawa H; Haku T; Takeuchi E; Suzuki Y; Nokihara H; Sone S
Lung Cancer; 2000 Feb; 27(2):67-73. PubMed ID: 10688489
[TBL] [Abstract][Full Text] [Related]
30. [Therapeutic efficacy of kanamycin and clofazimine combined with muramyl dipeptide against Mycobacterium intracellulare infection induced in mice].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Dec; 66(12):811-7. PubMed ID: 1784098
[TBL] [Abstract][Full Text] [Related]
31. Activation of mouse peritoneal adherent cells with N-acyl muramyl dipeptide derivatives.
Nishimura K; Okumura H; Saiki I; Okuyama H; Azuma I
Infect Immun; 1985 Mar; 47(3):665-9. PubMed ID: 3882562
[TBL] [Abstract][Full Text] [Related]
32. Specific binding sites of muroctasin on murine macrophages.
Akasaki M; Masayasu H; Tsukada W; Takegoshi T
Arzneimittelforschung; 1988 Jul; 38(7A):978-80. PubMed ID: 3190804
[TBL] [Abstract][Full Text] [Related]
33. Effects of treatment with muramyl dipeptide and certain of its analogs on resistance to Listeria monocytogenes in mice.
Humphres RC; Henika PR; Ferraresi RW; Krahenbuhl JL
Infect Immun; 1980 Nov; 30(2):462-6. PubMed ID: 7439991
[TBL] [Abstract][Full Text] [Related]
34. Effect of N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl- L-lysine on resistance to herpes simplex virus type-1 infection in cyclophosphamide-treated mice.
Ishihara C; Iida J; Mizukoshi N; Yamamoto N; Yamamoto K; Kato K; Azuma I
Vaccine; 1989 Aug; 7(4):309-13. PubMed ID: 2554602
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin.
Ogawa T; Kotani S; Shimauchi H
Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):117-25. PubMed ID: 3713372
[TBL] [Abstract][Full Text] [Related]
36. Immunoadjuvant effects of the synthetic muramyl-dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine.
Heymer B; Finger H; Wirsing CH
Z Immunitatsforsch Immunobiol; 1978 Oct; 155(1):87-92. PubMed ID: 706536
[TBL] [Abstract][Full Text] [Related]
37. Local tolerance of muroctasin injection in rabbits.
Nakashima K; Jindo T; Nomura M
Arzneimittelforschung; 1988 Jul; 38(7A):1038-9. PubMed ID: 3190798
[TBL] [Abstract][Full Text] [Related]
38. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine.
Koike Y; Yoo YC; Mitobe M; Oka T; Okuma K; Tono-oka S; Azuma I
Vaccine; 1998 Dec; 16(20):1982-9. PubMed ID: 9796054
[TBL] [Abstract][Full Text] [Related]
39. Production of colony-stimulating factor from macrophages by muroctasin.
Yamaguchi F; Akahane K; Takashi T; Tsukada W
Arzneimittelforschung; 1988 Jul; 38(7A):983-6. PubMed ID: 3263870
[TBL] [Abstract][Full Text] [Related]
40. Subacute toxicity of muroctasin in mice and dogs.
Ono Y; Iwasaki T; Sekiguchi M; Onodera T
Arzneimittelforschung; 1988 Jul; 38(7A):1024-7. PubMed ID: 3190795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
